Kyverna Therapeutics

Focus: Kyverna Therapeutics is a clinical-stage biotech company focused on developing Treg cell therapies to treat autoimmune diseases. The company operates in the high-growth cell and gene therapy space with a specialized focus on immunology.

Immunology Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Kyverna Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Kyverna Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

KYV-101

Refractory Lupus Nephritis

N/A

Clinical Trials (1)

NCT07403188A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

N/A

Help build intelligence for Kyverna Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Join a company pioneering Treg cell therapy, an emerging modality with significant unmet need in autoimmune disease treatment
Work in cutting-edge immunology and cell therapy, therapeutic areas attracting substantial venture and strategic investment
Early-stage environment offers opportunity for high impact on product development and organizational growth as the company advances clinical programs

Watch Out For

Pre-revenue biotech with no disclosed funding or cash position data limits visibility into runway and financial stability
Zero active job postings and absent employee count suggest early-stage scaling phase with limited near-term hiring

Generated by Claude from Kyverna Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

KYV-101

Idiopathic Inflammatory Myopathies

Phase 1

Clinical Trials (1)

NCT06152172CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

Phase 1

KYV-101

Progressive Multiple Sclerosis

Phase 1

Clinical Trials (1)

NCT06451159A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Phase 1

KYV-101 anti-CD19 CAR-T cell therapy

Multiple Sclerosis

Phase 1

Clinical Trials (1)

NCT06138132A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Phase 1

KYV-101 anti-CD19 CAR-T cell therapy

Lupus Nephritis

Phase 1/2

Clinical Trials (1)

NCT05938725KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Phase 1/2

KYV-101 anti-CD19 CAR-T cell therapy

Lupus Nephritis

Phase 1/2

Clinical Trials (1)

NCT06342960KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Phase 1/2

KYV101

Rheumatoid Arthritis

Phase 1/2

Clinical Trials (1)

NCT06475495Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis

Phase 1/2

KYV-101

Systemic Sclerosis

Phase 1/2

Clinical Trials (1)

NCT06400303KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Phase 1/2

KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy

ANCA-IgG-positive ANCA Associated Vasculitis

Phase 1/2

Clinical Trials (1)

NCT06590545Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis

Phase 1/2

KYV-101

Multiple Sclerosis, Primary Progressive

Phase 2

Clinical Trials (1)

NCT06384976KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Phase 2

Standard lymphodepletion regimen

Stiff-Person Syndrome

Phase 2

Clinical Trials (1)

NCT06588491KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

Phase 2

Standard of Care Treatment

Myasthenia Gravis

Phase 2/3

Clinical Trials (1)

NCT06193889KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Phase 2/3